Table 3.

Receiver operating characteristic (ROC) analysis between gene expression and pulmonary toxicity of nanomaterials.

Observation Time	3 Days	1 Week	1 Month	3 Months	6 Months
	AUC	AUC	AUC	AUC	AUC
	(95% C.I.)	(95% C.I.)	(95% C.I.)	(95% C.I.)	(95% C.I.)
	(Cut-off Value)	(Cut-off Value)	(Cut-off Value)	(Cut-off Value)	(Cut-off Value)
CXCL5	0.990	0.998	0.995	0.983	0.928
	(0.982–0.999)	(0.961–1.000)	(0.948–1.000)	(0.874–0.998)	(0.803–0.976)
	(10.008)	(10.308)	(9.513)	(3.277)	(1.934))
CCL2	0.693	0.973	0.980	0.910	0.848
	(0.501–0.835)	(0.841–0.996)	(0.904–0.996)	(0.753–0.971)	(0.674–0.937)
	(11.495)	(3.919)	(1.945)	(2.059)	(1.076)
CCL7	0.680	0.968	0.993	0.898	0.893
	(0.487–0.826)	(0.860–0.993)	(0.933–0.999)	(0.744–0.963)	(0.720–0.964)
	(12.380)	(5.090)	(1.990)	(2.007)	(1.020)
CXCL10	0.603	0.795	0.848	0.778	0.663
	(0.415–0.764)	(0.592–0.912)	(0.673–0.974)	(0.593–0.894)	(0.473–0.811)
	(8.311)	(2.088)	(1.620)	(1.466)	(1.097)
CXCL11	0.525	0.890	0.883	0.813	0.920
	(0.340–0.704)	(0.744–0.958)	(0.741–0.952)	(0.612–0.922)	(0.798–0.971)
	(7.843)	(2.790)	(2.073)	(1.025)	(0.706)

AUC: Area under the curve; 95% C.I.: 95% Confidence interval.